Pyxis Oncology Inc (PYXS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $188.98M
Last updated: Nov 17, 2026 at 11:05 AM ET
Pyxis Oncology Inc (PYXS) Stock Forecast
Analysts expect Pyxis Oncology (PYXS) to earn -$1.08 per share in the fiscal year ending Dec 31, 2026, on revenue of $19440. Of 10 analysts, 9 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 3 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 10 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 90% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 10.0% |
| Buy | 8 | 80.0% |
| Hold | 1 | 10.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 10
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$1.08
- EPS consensus, revenue $19440
- Fiscal year ending Dec 31, 2027
- -$0.86
- EPS consensus
- Next report
- Mar 22, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.08 | -$1.31 to -$0.72 | 9 | $19440 | N/A | 9 |
| Dec 31, 2027 | -$0.86 | -$1.54 to -$0.46 | 9 | N/A | N/A | 9 |
Quarterly Estimates
The EPS consensus rises from -$0.23 for the quarter ending Dec 31, 2026 to -$0.21 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.23 | -$0.30 to -$0.16 | 11 | $19829 | N/A | 11 |
| Mar 31, 2027 | -$0.21 | -$0.29 to -$0.16 | 4 | N/A | N/A | 4 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 5 upward and 1 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 3 | 0 |
| Quarter ending Mar 31, 2027 | 2 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$1.22.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.08 | -$1.21 | -$1.21 | -$1.22 | -$1.22 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.86 | -$1.11 | -$1.11 | -$1.13 | -$1.20 | N/A |
| Quarter ending Mar 31, 2027 | -$0.21 | -$0.23 | -$0.23 | -$0.23 | -$0.25 | N/A |
Frequently Asked Questions About PYXS
What is the PYXS stock forecast?
Consensus analyst estimates put Pyxis Oncology's EPS at -$1.08 for the fiscal year ending Dec 31, 2026, on revenue of $19440. The consensus rating from 10 analysts is Buy.
How do analysts rate PYXS stock?
Of 10 analysts covering Pyxis Oncology, 1 rates it Strong Buy, 8 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from PYXS next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.08, with estimates from -$1.31 to -$0.72 from 9 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.86, with estimates from -$1.54 to -$0.46 from 9 analysts.
What revenue do analysts expect from Pyxis Oncology next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $19440.
How many analysts cover PYXS?
10 analysts rate Pyxis Oncology stock, and 9 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
PYXS pages: Overview, Earnings, Forecast, Financials, Competitors